Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.32 |
| ▸ | CDK2 | P24941 | 4/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725892 | 0.90 | PIK3CA (0.34) | PIK3CAAKT1MTOR | |
| SCHEMBL10238716 | 0.89 | PIK3CA (0.31) | PIK3CAAKT1MTOR | |
| SCHEMBL10327978 | 0.89 | PIK3CA (0.32) | PIK3CAAKT1MTOR | |
| SCHEMBL7874285 | 0.88 | CHEK1 (0.34) | CHEK1CCNA2CDK2CCNA1PIK3CA | |
| SCHEMBL594420 | 0.87 | PIK3CA (0.33) | CHEK1CCNA2CDK2CCNA1PIK3CA | |
| SCHEMBL2680181 | 0.87 | DGAT1 (0.36) | CHEK1CCNA2CDK2CCNA1PIK3CA | |
| SCHEMBL7886269 | 0.87 | PIK3CA (0.33) | CHEK1CCNA2CDK2CCNA1PIK3CA | |
| SCHEMBL6889657 | 0.87 | DGAT1 (0.39) | CHEK1CCNA2CDK2CCNA1MTOR | |
| SCHEMBL590602 | 0.87 | HDAC1 (0.33) | — | |
| SCHEMBL2680019 | 0.86 | CHEK1 (0.31) | CHEK1CCNA2CDK2CCNA1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2011002887-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 185/4885CCNA2 203/4885CDK2 31/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.